Hanmi's short bowel syndrome drug gets FDA fast track status

Korea Biomedical Review

7 April 2021 - Hanmi Pharmaceutical said Wednesday that the U.S. Food and Drug Administration has granted fast-track designation to its short-bowel syndrome therapy, LAPS GLP-2 Analog (HM15912).

LAPS GLP-2 Analog is a new biopharmaceutical being developed for short-bowel syndrome with the company's platform technology, known as Labscovery.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track